Draft talk:CellxLife
Add topicPaid edit request: Pharmaphorum coverage
[edit] | A new editor with an actual or apparent conflict of interest has requested assistance with making an addition to this article. The requested edits backlog is very high. Please be extremely patient. There are currently 644 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies. |
I am a paid marketing consultant for CellxLife and Ruvin Orbach. My paid relationship is disclosed on my user page. I am therefore requesting review by an uninvolved editor rather than editing the article directly.
I propose adding the following sentence to the section discussing CellxLife's ovarian cancer programme or Mayo Clinic licensing agreement:
"In July 2026, Pharmaphorum reported on CellxLife's licensing agreement with Mayo Clinic for a dendritic-cell cancer vaccine being studied in two Phase II ovarian cancer trials."[1]
Reason for the request: The article is published by Pharmaphorum and written by its web editor. The proposed sentence is deliberately limited to the licensing agreement and clinical-trial status described in the publication. I am not proposing the addition of the treatment-effectiveness claims attributed to CellxLife's CEO in the interview portion of the article.
I welcome any revisions an uninvolved editor considers necessary for neutrality, sourcing, due weight, or placement. TaraJacobs12 (talk) 22:26, 30 July 2026 (UTC) TaraJacobs12 (talk) 22:26, 30 July 2026 (UTC)
Paid COI edit request: Los Angeles Business Journal coverage
[edit] | The user below has a request that an edit be made to Draft:CellxLife. That user has an actual or apparent conflict of interest. The requested edits backlog is very high. Please be extremely patient. There are currently 644 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies. |
I am a paid marketing consultant for CellxLife and Ruvin Orbach, as disclosed on my user page. I am submitting this request for review by an uninvolved editor rather than editing the article directly.
I propose adding the following text to the section discussing the company's technology, licensing activities, or clinical development:
"In July 2026, the Los Angeles Business Journal reported that CellxLife had licensed an ovarian cancer immunotherapy from Mayo Clinic for further clinical development. The publication described CellxLife's business model as including both the development of its own therapies and the acquisition of licensing rights to therapies developed by other institutions."[2]
The source also reports that the licensed therapy uses dendritic cells to stimulate an immune response against ovarian cancer and that CellxLife planned to continue its clinical development. I have kept the proposed wording limited to the licensing agreement and the company's reported development model, without repeating promotional statements or presenting preliminary clinical findings as established treatment outcomes.
I welcome any changes an uninvolved editor considers necessary for neutrality, due weight, sourcing, wording, or placement. TaraJacobs12 (talk) 22:32, 30 July 2026 (UTC) TaraJacobs12 (talk) 22:32, 30 July 2026 (UTC)
- ↑ Raleigh, Nicole (30 July 2026). "Solving the ovarian cancer diagnostic and treatment pathway problem". Pharmaphorum. Retrieved 30 July 2026.
- ↑ Welk, Hannah (13 July 2026). "CellxLife to Get Mayo Clinic Drug". Los Angeles Business Journal. Retrieved 30 July 2026.